The Federation informs you about the reimbursement of a new continuous glucose measurement system: Dexcom ONE +.
Good news for people with diabetes: the Dexcom ONE+ system is reimbursed for patients on intensified insulin therapy or non-intensified insulin therapy*. The Dexcom company has just announced that this device is also available in pharmacies since October 7. With in particular a waterproof sensor, which initializes in 30 minutes and a smaller size than the Dexcom ONE sensor, the reimbursement of this device helps improve the daily lives of people living with diabetes.
Prescription and management indications for Dexcom ONE +
According to the decree, this system is aimed at:
– type 1 or type 2 diabetic patients, adults and children aged at least 2 years treated with intensified insulin therapy (by external pump or ≥ 3 injections per day), in addition to self-monitoring of capillary blood glucose,
– type 2 diabetic patients, adults and children aged at least 2 years treated with non-intensified insulin therapy, whose glycemic control is insufficient (HbA1c ≥ 8%).
Support excludes its use with a closed or semi-closed loop system.
The duration of wearing the sensors is 10 days with an additional period of 12 hours at the end of the session allowing the sensor to be changed. The number of sensors supported per year per patient is limited to 36 sensors.
The initial prescription of the Dexcom ONE system, subject to a trial period of 1 to 3 months, as well as its renewal are provided by a diabetologist or pediatrician experienced in diabetology or by a general practitioner for patients treated with non-intensified insulin therapy. .
To find out more about how to prescribe the device and your eligibility, your diabetologist or general practitioner will provide good advice.
*Sources :
Dexcom, Inc. Simple, discreet and effective: the new Dexcom ONE + glucose sensor is now reimbursed and available in pharmacies from October 7. Press release, October 7, 2024.
Order of September 11, 2024 registering the DEXCOM ONE + continuous interstitial glucose measurement system from the company DEXCOM France in Title I of the list of reimbursable products and services provided for in Article L. 165-1 of the Security Code social
Photo credit: Dexcom
Related News :